Navigation Links
Selexis SA to Partner and Exhibit at BIO 2011 in Washington DC

GENEVA, June 1, 2011 /PRNewswire/ -- Selexis SA, a Swiss-based biotechnology company with technologies for the rapid development and engineering of high yield and stable mammalian cell lines for therapeutic protein manufacturing of recombinant drugs announced today representatives from the Company will be participating in the 2011 BIO International Convention's One-on-One Partnering Meetings being held Jun 27-30 in Washington, D.C. at the Walter E. Washington Convention Center.

Selexis has interactive collaborations, partnerships and commercial deals with leading biotechnology and pharmaceutical companies worldwide. Selexis' SURE technology platform allows for faster and more reliable cell line development with higher expression levels which can be applied to a wide range of areas such as bio-manufacturing, drug discovery, diagnostics and therapeutics.

Representatives available to discuss Selexis' capabilities include: Dr. Igor Fisch, CEO; Andrew Sandford, VP Business Development and Licensing; Dr. Armelle Gaussin, Chief Technology Officer; and Dr. Denise Huber, Director of Business Development. Companies or individuals attending BIO 2011 can schedule meetings with Selexis by visiting (registration required):

Selexis Partnering Schedule:

Monday, June 27 Business Forum  -  12:00 PM - 5:00 PM

Tuesday, June 28 Business Forum  -  7:00 AM – 6:00 PM

Wednesday, June 29 Business Forum  -  7:00 AM – 6:00 PM

Thursday, June 30 Business Forum  -  7:00 AM – 6:00 PM

For companies or individuals not participating in partnering meetings, Selexis will be exhibiting in booth number #1906 located in Hall A – Discovery Zone ( For the exhibit hall schedule, visit:

About Selexis SA

Headquartered in Geneva, Switzerland, Selexis SA is a privately held biotechnology company dedicated to the development of innovative technologies and world-class expert services that significantly reduce the time, effort, and costs associated with developing high-performance mammalian cell lines for therapeutic protein production (i.e. MAbs, growth factors, enzymes). The Company's SURE Cell Line Development™ Technology Platform is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. The technology platform also includes Selexis SUREtech Vectors™, Selexis SUREfection™ Transfection Methods, Selexis SUREvariant Screening™ and the proprietary Selexis SURE CHO-M Cell Line™.

For more information visit

Robert Meister
(602) 953-1716

Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Selexis SA and the University of Lausanne Announce the Complete Sequencing of the Selexis SURE CHO-M Genome
2. Selexis SA Doubles Cell Line Development Laboratory Space in Geneva, Switzerland
3. Irvine Scientific and Selexis to Announce Results of Successful Collaboration
4. Selexis Launches Biosimilar Cell Line Development Program
5. Pfizer Inc. and PAREXEL International Corp. Sign Strategic Partnership Agreement to Advance Clinical Development
6. Local Partnership Addresses Lagging Scores and Interest in Science and Math Among Students
7. Jennerex and Partners Present Positive JX-594 Randomized Phase 2 Clinical Data Showing Promising Survival Benefit in Patients with Advanced Liver Cancer
8. Northwest Biotherapeutics and the Fraunhofer Institute for Cell Therapy and Immunology are Partnering for Clinical Trials and Compassionate Use Cases in Europe
9. Rules-Based Medicine, Inc. (RBM) Partners with Institut Pasteur to Boost Innovation in Translational Research
10. Aperio Partners with Definiens to Market Definiens Tissue Studio for Advanced Image Analysis
11. John McKearn, Ph.D., Promoted to Managing Director of RiverVest Venture Partners
Post Your Comments:
(Date:11/24/2015)... FAR HILLS, N.J. (PRWEB) , ... November 24, 2015 , ... ... University, as the recipient of the 2016 USGA Green Section Award. Presented annually since ... of golf through his or her work with turfgrass. , Clarke, of ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... 24, 2015 --> ... report "Oligonucleotide Synthesis Market by Product & Services (Primer, ... Diagnostic, DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic ... the market is expected to reach USD 1,918.6 Million ... a CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... , November 24, 2015 ... recent market research report released by Transparency Market Research, ... expand at a CAGR of 17.5% during the period ... Testing Market - Global Industry Analysis, Size, Volume, Share, ... global non-invasive prenatal testing market to reach a valuation ...
Breaking Biology Technology:
(Date:11/19/2015)...  Although some 350 companies are actively involved in ... companies, according to Kalorama Information. These include Roche Diagnostics, Hologic, ... share of the 6.1 billion-dollar molecular testing market, according ... Molecular Diagnostic s .    ... by one company and only a handful of companies ...
(Date:11/18/2015)... , November 18, 2015 ... published a new market report titled  Gesture Recognition Market ... Forecast, 2015 - 2021. According to the report, the global gesture ... is anticipated to reach US$29.1 bn by 2021, at ... North America dominated the global ...
(Date:11/17/2015)... Paris , qui s,est tenu ... Paris , qui s,est tenu du 17 au ... l,innovation biométrique, a inventé le premier scanner couplé, qui ... même surface de balayage. Jusqu,ici, deux scanners étaient nécessaires, ... digitales. Désormais, un seul scanner est en mesure de ...
Breaking Biology News(10 mins):